Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Completed 26 weeks of double-blind phase of Study ONO-4641POU006~Exclusion Criteria:~* Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ONO-4641 0.15 milligram (mg) - 0.15 mg (Type: EXPERIMENTAL): None
- ONO-4641 0.10 mg - 0.10 mg (Type: EXPERIMENTAL): None
- ONO-4641 0.05 mg - 0.05 mg (Type: EXPERIMENTAL): None
- Placebo - ONO4641 0.15 mg (Type: EXPERIMENTAL): None
- Placebo - ONO4641 0.10 mg (Type: EXPERIMENTAL): None
- Placebo - ONO4641 0.05 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).